Skip to content
Spiritual Quotes – Lifestyle
Author:
Prime Medicine, Inc.
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
October 5, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
September 24, 2026
Prime Medicine to Participate in Upcoming Investor Conferences
September 3, 2026
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
July 23, 2026
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
July 8, 2026
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
June 22, 2026
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
June 18, 2026
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
June 3, 2026
Prime Medicine to Present at Jefferies Global Healthcare Conference
May 28, 2026
1
2
Next Page
→